| Name | Lobradimil |
|---|---|
| Synonyms |
DRG0182
Labradimil LabradiMil,LabrodiMil,RMP-7,LobradiMil DRG-0182 (Hyp3,b-(2-thienyl)-Ala5,Tyr(Me)8-g9)-Bradykinin (Hyp3,β-(2-thienyl)-Ala,Tyr(Me)-psi(CHNH)g)-Bradykinin trifluoroacetate salt (Hyp3,β-(2-thienyl)-Ala5,Tyr(Me)8-psi(CH2NH)g9)-Bradykinin (Hyp3,β-(2-thienyl)-Ala5,Tyr(Me)8-g9)-Bradykinin Lobradimil RMP 7 H-g-Pro-Hyp-Gly-b-(2-thienyl)-Ala-Ser-Pro-Tyr(Me)-g-OH (Hyp,β-(2-thienyl)-Ala,Tyr(Me)-psi(CHNH)g)-Bradykinin (Hyp3,beta-(2-thienyl)-Ala5,Tyr(Me)8-(R)-g9)-Bradykinin Rector-mediated permeabiliser-7 L-ginine, L-ginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolyl-O-methyl-L-tyrosyl-ψ(CH2-NH) (Hyp 3,b-(2-thienyl)-Ala5,Tyr(Me)8-psi(CH2NH)g9)-Bradykinin trifluoroacetate salt DRG 0182 H-Arg-Pro-Hyp-Gly-b-(2-thienyl)-Ala-Ser-Pro-Tyr(Me)-()-Arg-OH H-g-Pro-Hyp-Gly-b-(2-thienyl)-Ala-Ser-Pro-Tyr(Me)-psi(CH2NH)g-OH (Hyp3,b-(2-thienyl)-Ala5,Tyr(Me)8-psi(CH2NH)g9)-Bradykinin (H-6578.0005) LabradiMil, LabrodiMil, RMP-7, LobradiMil ALK-01-040 (Hyp3,β-(2-thienyl)-Ala5,Tyr(Me)8-(R)-g9)-Bradykinin (Hyp3,β-(2-thienyl)-Ala5,Tyr(Me)8-()-g9)-Bradykinin Lobradimil (Hyp3,b-(2-thienyl)-Ala5,Tyr(Me)8-()-Arg9)-Bradykinin |
| Description | Lobradimil (RMP 7), a synthetic bradykinin analog, is a potent and selective bradykinin B2 receptor agonist (Ki: 0.54 nM). Lobradimil increases the permeability of the BBB. Lobradimil can be used in the research of brain tumors[1]. |
|---|---|
| Related Catalog | |
| Target |
Bradykinin B2 Receptor (B2R):0.54 nM (Ki) |
| In Vitro | Lobradimil induces an increase in intracellular free calcium levels in RBME cells[3]. Lobradimil (0.01-0.5 nM, 15 min) increases the permeability of human brain microvascular endothelial cell (HMBEC) monolayers1[4]. |
| In Vivo | Lobradimil (2.5-mg/kg bolus plus 10 mg/kg/h for 90 minutes) increases brain tumor permeability and shows hypotensive effects in RG2 glioma cells-implanted rats[2]. Animal Model: RG2 glioma cells-implanted rats[2] Dosage: 1.5-18 μg/kg Administration: i.v. infusion, 0.05 mL/min for 15min Result: Increased Carboplatin (HY-17393) uptake (up to 80%) into brain tumors in a dose-dependent manner. |
| Density | 1.53 |
|---|---|
| Molecular Formula | C49H75N15O12S |
| Molecular Weight | 1098.28000 |
| Exact Mass | 1097.54000 |
| PSA | 454.41000 |
| LogP | 0.79560 |
| Index of Refraction | 1.702 |